CAR T-cell recognition and destruction of tumor cells occur in an independent-manner of MHCs; this promotes enhanced cell recognition undisturbed by the tumor’s ability to avoid MHC-restricted recognition of T-cells, such as the tumor’s ability to encourage defective antigen processing by downregulating human leukocyte antigen (HLA) class I molecules (Dotti et al., 2014). Here, HLA-C is linked to neoplasm.